EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antipsychotic Prescriptions for Prenatal and Postpartum Women in Japan: A Large Claims Database Study

Ryo Obara iD, Takamasa Sakai iD, Tomofumi Ishikawa iD, Kei Morishita iD, Motohiko Adomi iD, Azusa Hara iD, Saya Kikuchi iD, Natsuko Kobayashi iD, Noriyuki Iwama iD, Genki Shinoda iD, Aoi Noda iD, Masatsugu Orui iD und 5 weitere

Pharmacology Research & Perspectives · 2026

DOI: 10.1002/prp2.70336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Ryo Obara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Antipsychotic Agents, Drug Prescriptions, Pregnancy Complications, Practice Patterns, Physicians'. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Health, Labour and Welfare of Japan, Japan Society for the Promotion of Science (JSPS KAKENHI), the Research Institute of Healthcare Data Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the prevalence of antipsychotic prescriptions before, during, and after pregnancy in Japan, with a focus on new prescriptions and continuation after pregnancy confirmation. We conducted a claims‐based analysis using a Japanese claims database (analytic period: 2010–2022). Antipsychotic prescription prevalence and new prescriptions were assessed from 180 days before pregnancy through 180 days postpartum. To assess continuation after pregnancy confirmation, prescription status was evaluated across gestational weeks 0–4, 5–13, and from 14 weeks to delivery. Among 120 735 women, 1698 (140.6/10 000 deliveries) received at least one antipsychotic prescription, including 809 (67.0/10 000 deliveries) during pregnancy. Prescription prevalence decreased during the first and second trimesters but increased postpartum. New prescriptions were less frequent during pregnancy but increased after delivery. Among 611 women prescribed antipsychotics during 0–4 weeks' gestation, 482 (78.9%) continued and 129 (21.1%) discontinued prescription during weeks 5–13; of those who continued prescription during 5–13 weeks, 334 (54.7%) continued until delivery. Evaluation of major indications showed that continuation until delivery was highest in those with schizophrenia (63.6%), followed by bipolar disorder (51.0%). This study provides the first comprehensive description of perinatal antipsychotic prescription trends in Japan. Substantial prescription discontinuation occurred after pregnancy confirmation. Increases in postpartum prescriptions might reflect new prescriptions or resumption among women who had discontinued treatment during pregnancy. These findings offer foundational epidemiological insights into real‐world perinatal antipsychotic use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsDrug PrescriptionsPregnancy ComplicationsPractice Patterns, Physicians'HumansFemaleJapanPregnancyDatabases, FactualPostpartum PeriodAdult

Stichwörter der Autor:innen

Japanantipsychoticpostpartumprenatalprescriptionpsychiatric disordersschizophrenia

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Division of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.
  • Drug Informatics, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
  • Laboratory of Biomolecule and Pathophysiological Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Laboratory of Social Pharmacy and Epidemiology, Showa Pharmaceutical University, Machida, Tokyo, Japan.

ORCID-Profile: Ryo Obara, Takamasa Sakai, Tomofumi Ishikawa, Kei Morishita, Motohiko Adomi, Azusa Hara, Saya Kikuchi, Natsuko Kobayashi, Noriyuki Iwama, Genki Shinoda, Aoi Noda, Masatsugu Orui, Hiroaki Tomita, Nariyasu Mano, Shinichi Kuriyama, Taku Obara

Förderung

  • the Ministry of Health, Labour and Welfare of Japan
  • Japan Society for the Promotion of Science (JSPS KAKENHI)
  • the Research Institute of Healthcare Data Science
  • Ministry of Health Mexico

Zitieren

APA

Obara, R., Sakai, T., Ishikawa, T., Morishita, K., Adomi, M., Hara, A., Kikuchi, S., Kobayashi, N., Iwama, N., Shinoda, G., Noda, A., Orui, M., Ishikuro, M., Tomita, H., Mano, N., Kuriyama, S., & Obara, T. (2026). Antipsychotic Prescriptions for Prenatal and Postpartum Women in Japan: A Large Claims Database Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70336

Vancouver

Obara R, Sakai T, Ishikawa T, Morishita K, Adomi M, Hara A, et al. Antipsychotic Prescriptions for Prenatal and Postpartum Women in Japan: A Large Claims Database Study. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70336

BibTeX
@article{Obara2026,
  author = {Obara, Ryo and Sakai, Takamasa and Ishikawa, Tomofumi and Morishita, Kei and Adomi, Motohiko and Hara, Azusa and Kikuchi, Saya and Kobayashi, Natsuko and Iwama, Noriyuki and Shinoda, Genki and Noda, Aoi and Orui, Masatsugu and Ishikuro, Mami and Tomita, Hiroaki and Mano, Nariyasu and Kuriyama, Shinichi and Obara, Taku},
  title = {Antipsychotic Prescriptions for Prenatal and Postpartum Women in Japan: A Large Claims Database Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  doi = {10.1002/prp2.70336}
}
Kostenlos starten →